يعرض 1 - 10 نتائج من 194 نتيجة بحث عن '"Demidov, L"', وقت الاستعلام: 2.03s تنقيح النتائج
  1. 1
    دورية أكاديمية
    More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments

    المؤلفون: Sekulovic, LK, Peris, K, Hauschild, A, Stratigos, A, Grob, JJ, Nathan, P, Dummer, R, Forsea, AM, Hoeller, C, Gogas, H, Demidov, L, Lebbe, C, Blank, C, Olah, J, Bastholt, L, Herceg, D, Neyns, B, Vieira, R, Hansson, J, Rutkowski, P, Krajsova, I, Bylaite-Bucinskiene, M, Zalaudek, I, Maric-Brozic, J, Babovic, N, Banjin, M, Putnik, K, Weinlich, G, Todorovic, V, Kirov, K, Ocvirk, J, Zhukavets, A, Kukushkina, M, Merino, LD, Ymeri, A, Risteski, M, Garbe, C

    المصدر: European journal of cancer (Oxford, England : 1990). 75:313-322

    مصطلحات موضوعية: Medicin och hälsovetenskap, Klinisk medicin, Cancer och onkologi, Hälsovetenskap, Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi

    الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:135709754Test

    View record in SwePub

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF(V600) mutation-positive melanoma

    المؤلفون: Robert, C, Lewis, KD, Gutzmer, R, Stroyakovskiy, D, Gogas, H, Protsenko, S, Pereira, RP, Eigentler, T, Rutkowski, P, Demidov, L, Caro, I, Forbes, H, Shah, K, Yan, Y, Li, H, McArthur, GA, Ascierto, PA

    العلاقة: pii: S0923-7534(22)00103-X; Robert, C., Lewis, K. D., Gutzmer, R., Stroyakovskiy, D., Gogas, H., Protsenko, S., Pereira, R. P., Eigentler, T., Rutkowski, P., Demidov, L., Caro, I., Forbes, H., Shah, K., Yan, Y., Li, H., McArthur, G. A. & Ascierto, P. A. (2022). Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF(V600) mutation-positive melanoma. ANNALS OF ONCOLOGY, 33 (5), pp.544-555. https://doi.org/10.1016/j.annonc.2022.01.076Test.; http://hdl.handle.net/11343/308716Test

    الإتاحة: https://doi.org/10.1016/j.annonc.2022.01.076Test
    http://hdl.handle.net/11343/308716Test

    View record in BASE النص الكامل

    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.

    المؤلفون: Ascierto, PA, Dréno, B, Larkin, J, Ribas, A, Liszkay, G, Maio, M, Mandalà, M, Demidov, L, Stroyakovskiy, D, Thomas, L, de la Cruz-Merino, L, Atkinson, V, Dutriaux, C, Garbe, C, Hsu, J, Jones, S, Li, H, McKenna, E, Voulgari, A, McArthur, GA

    المساهمون: Larkin, James

    مصطلحات موضوعية: Antineoplastic Combined Chemotherapy Protocols, Azetidines, Follow-Up Studies, Humans, Melanoma, Mutation, Piperidines, Proto-Oncogene Proteins B-raf, Skin Neoplasms, Vemurafenib

    جغرافية الموضوع: United States

    وصف الملف: Print; 5235; application/pdf

    العلاقة: 1078-0432.CCR-21-0809; Clinical Cancer Research, 2021, 27 (19), pp. 5225 - 5235; https://repository.icr.ac.uk/handle/internal/5284Test

    الإتاحة: https://doi.org/10.1158/1078-0432.CCR-21-0809Test
    https://repository.icr.ac.uk/handle/internal/5284Test

    View record in BASE النص الكامل

    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.

    المؤلفون: Dréno, B, Ascierto, PA, Atkinson, V, Liszkay, G, Maio, M, Mandalà, M, Demidov, L, Stroyakovskiy, D, Thomas, L, de la Cruz-Merino, L, Dutriaux, C, Garbe, C, Bartley, K, Karagiannis, T, Chang, I, Rooney, I, Koralek, DO, Larkin, J, McArthur, GA, Ribas, A

    المساهمون: Larkin, James

    مصطلحات موضوعية: Antineoplastic Combined Chemotherapy Protocols, Azetidines, Double-Blind Method, Female, Humans, Longitudinal Studies, Male, Melanoma, Mutation, Piperidines, Placebos, Proto-Oncogene Proteins B-raf, Quality of Life, Vemurafenib

    جغرافية الموضوع: England

    وصف الملف: Print-Electronic; 784; application/pdf

    العلاقة: bjc2017488; British Journal of Cancer, 2018, 118 (6), pp. 777 - 784; https://repository.icr.ac.uk/handle/internal/5296Test

    الإتاحة: https://doi.org/10.1038/bjc.2017.488Test
    https://repository.icr.ac.uk/handle/internal/5296Test

    View record in BASE النص الكامل

    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    LBA39 Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL)

    المؤلفون: Dummer, R., Gyorki, D., Hyngstrom, J., Berger, A., Conry, R., Demidov, L., Ning, L., Lawrence, T., Faries, M., Ross, M.

    المساهمون: Amgen

    المصدر: Annals of Oncology ; volume 33, page S1406 ; ISSN 0923-7534

    مصطلحات موضوعية: Oncology, Hematology

    الإتاحة: https://doi.org/10.1016/j.annonc.2022.08.037Test
    https://api.elsevier.com/content/article/PII:S0923753422039151?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0923753422039151?httpAccept=text/plainTest

    View record in BASE

    أضف إلى المفضلة
  6. 6
    دورية أكاديمية
    806P Updated toxicity profile and relapse-free survival outcomes using an adapted pyrexia management algorithm in patients with resected stage III BRAF V600E/K-mutant melanoma treated with adjuvant dabrafenib plus trametinib in COMBI-APlus

    المؤلفون: Del Vecchio, M., Atkinson, V.G., Ryll, B., Menzies, A.M., Aubin, F., Chiarion Sileni, V., Ferraresi, V., Lesimple, T., Rinaldi, G., Saiag, P., Robert, C., Dutriaux, C., Gogas, H.J., Demidov, L., Gupta, A., Banerjee, H., Sudhir, S., Miranda, F., Lau, M.R., Grob, J.J.

    المصدر: Annals of Oncology ; volume 33, page S914 ; ISSN 0923-7534

    مصطلحات موضوعية: Oncology, Hematology

    الإتاحة: https://doi.org/10.1016/j.annonc.2022.07.932Test
    https://api.elsevier.com/content/article/PII:S0923753422027831?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0923753422027831?httpAccept=text/plainTest

    View record in BASE

    أضف إلى المفضلة
  7. 7
    دورية أكاديمية
    Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma

    المؤلفون: Robert, C., Lewis, K.D., Gutzmer, R., Stroyakovskiy, D., Gogas, H., Protsenko, S., Pereira, R.P., Eigentler, T., Rutkowski, P., Demidov, L., Caro, I., Forbes, H., Shah, K., Yan, Y., Li, H., McArthur, G.A., Ascierto, P.A.

    المساهمون: F. Hoffmann-La Roche Ltd

    المصدر: Annals of Oncology ; volume 33, issue 5, page 544-555 ; ISSN 0923-7534

    مصطلحات موضوعية: Oncology, Hematology

    الإتاحة: https://doi.org/10.1016/j.annonc.2022.01.076Test
    https://api.elsevier.com/content/article/PII:S092375342200103X?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S092375342200103X?httpAccept=text/plainTest

    View record in BASE

    أضف إلى المفضلة
  8. 8
    دورية أكاديمية
    5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF(V600) Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

    المؤلفون: Ascierto, PA, Dreno, B, Larkin, J, Ribas, A, Liszkay, G, Maio, M, Mandala, M, Demidov, L, Stroyakovskiy, D, Thomas, L, de la Cruz-Merino, L, Atkinson, V, Dutriaux, C, Garbe, C, Hsu, J, Jones, S, Li, H, McKenna, E, Voulgari, A, McArthur, GA

    العلاقة: pii: 1078-0432.CCR-21-0809; Ascierto, P. A., Dreno, B., Larkin, J., Ribas, A., Liszkay, G., Maio, M., Mandala, M., Demidov, L., Stroyakovskiy, D., Thomas, L., de la Cruz-Merino, L., Atkinson, V., Dutriaux, C., Garbe, C., Hsu, J., Jones, S., Li, H., McKenna, E., Voulgari, A. & McArthur, G. A. (2021). 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF(V600) Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. CLINICAL CANCER RESEARCH, 27 (19), pp.5225-5235. https://doi.org/10.1158/1078-0432.CCR-21-0809Test.; http://hdl.handle.net/11343/307859Test

    الإتاحة: https://doi.org/10.1158/1078-0432.CCR-21-0809Test
    http://hdl.handle.net/11343/307859Test

    View record in BASE النص الكامل

    أضف إلى المفضلة
  9. 9
    دورية أكاديمية
    Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

    المؤلفون: Gogas, H., Dréno, B., Larkin, J., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Francesco Ferrucci, P., Pigozzo, J., Rutkowski, P., Mackiewicz, J., Rooney, I., Voulgari, A., Troutman, S., Pitcher, B., Guo, Y., Yan, Y., Castro, M., Mulla, S., Flaherty, K., Arance, A.

    المساهمون: F. Hoffmann-La Roche, Genentech Inc

    المصدر: Annals of Oncology ; volume 32, issue 3, page 384-394 ; ISSN 0923-7534

    مصطلحات موضوعية: Oncology, Hematology

    الإتاحة: https://doi.org/10.1016/j.annonc.2020.12.004Test
    https://api.elsevier.com/content/article/PII:S092375342043203X?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S092375342043203X?httpAccept=text/plainTest

    View record in BASE

    أضف إلى المفضلة
  10. 10
    دورية أكاديمية
    1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)

    المؤلفون: Ribas, A., Chesney, J., Long, G.V., Kirkwood, J.M., Dummer, R., Puzanov, I., Hoeller, C., Gajewski, T.F., Gutzmer, R., Rutkowski, P., Demidov, L., Arenberger, P., Shin, S.J., Ferrucci, P.F., Diede, S.J., Anderson, J.R., Treichel, S., Chan, E., Hodi, F.S., Gogas, H.J.

    المساهمون: Amgen

    المصدر: Annals of Oncology ; volume 32, page S868-S869 ; ISSN 0923-7534

    مصطلحات موضوعية: Oncology, Hematology

    الإتاحة: https://doi.org/10.1016/j.annonc.2021.08.1422Test
    https://api.elsevier.com/content/article/PII:S0923753421036516?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0923753421036516?httpAccept=text/plainTest

    View record in BASE

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث